This document can be found online at: www.evidence.nhs.uk/qipp Antigen-specific active immunotherapy for ovarian cancer NICE has developed the Cochrane Quality and Productivity topics to help the NHS identify practices that could be significantly reduced or stopped completely, releasing cash and/or resources without negatively affecting the quality of NHS care. Each topic has been derived from a Cochrane systematic review that has concluded that the evidence shows that the practice is harmful or ineffective and should not be used, or that there is insufficient evidence to support widespread use of the practice.
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Evidence
Relevance to the NHS A Cochrane review found no high-quality evidence that immunotherapy improves patients' survival. Response definitions showed substantial variation between trials, which makes comparison of trial results unreliable. Information on adverse events was frequently limited. The review looked at 55 studies (representing 3051 women with epithelial ovarian cancer); 43 were uncontrolled phase I or II studies. The most commonly tested approach was antibodies to the tumour antigen CA-125. Four large randomised controlled trials compared survival between women treated with the antibody, and women given placebo, but no difference was seen. 
Relevant NICE guidance and products Ovarian cancer: The recognition and initial management of ovarian cancer -NICE Clinical

Potential productivity savings Estimate of current NHS use
There is no information available on the current use of antigen-specific active immunotherapy for ovarian cancer
Level of productivity savings anticipated Cannot be quantified.
